<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="34f97a49-2654-18d1-e063-6394a90acaff"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use LEVETIRACETAM IN SODIUM CHLORIDE INJECTION safely and effectively. See full prescribing information for LEVETIRACETAM IN SODIUM CHLORIDE INJECTION.
 <br/>
      <br/>
LEVETIRACETAM IN SODIUM CHLORIDE injection, for intravenous use
 <br/>
Initial U.S. Approval: 1999
 <br/>
   </title>
   <effectiveTime value="20250512"/>
   <setId root="da023a3c-e4c7-49a3-968e-9ae33ea7feda"/>
   <versionNumber value="6"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="080318964"/>
            <name>Athenex Pharmaceutical Division, LLC.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="34f9886a-5b36-4a5e-e063-6294a90a41e1"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250512"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70860-602" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Levetiracetam</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Levetiracetam</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Q40Q9N063P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ACETIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4550K0SC9B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM ACETATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="5"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="44YRR34555" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LEVETIRACETAM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="44YRR34555" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LEVETIRACETAM</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="70860-602-41" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                                    <asContent>
                                       <quantity>
                                          <numerator value="10" unit="1"/>
                                          <denominator value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code code="70860-602-82" codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                       </containerPackagedProduct>
                                       <subjectOf>
                                          <marketingAct>
                                             <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                             <statusCode code="completed"/>
                                             <effectiveTime>
                                                <low value="20180530"/>
                                                <high value="20260331"/>
                                             </effectiveTime>
                                          </marketingAct>
                                       </subjectOf>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA206880" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="completed"/>
                           <effectiveTime>
                              <low value="20180530"/>
                              <high value="20260331"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70860-603" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Levetiracetam</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Levetiracetam</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Q40Q9N063P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ACETIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4550K0SC9B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM ACETATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="10"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="44YRR34555" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LEVETIRACETAM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="44YRR34555" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LEVETIRACETAM</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="70860-603-41" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                                    <asContent>
                                       <quantity>
                                          <numerator value="10" unit="1"/>
                                          <denominator value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code code="70860-603-82" codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                       </containerPackagedProduct>
                                       <subjectOf>
                                          <marketingAct>
                                             <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                             <statusCode code="completed"/>
                                             <effectiveTime>
                                                <low value="20180530"/>
                                                <high value="20260331"/>
                                             </effectiveTime>
                                          </marketingAct>
                                       </subjectOf>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA206880" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="completed"/>
                           <effectiveTime>
                              <low value="20180530"/>
                              <high value="20260331"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70860-604" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Levetiracetam</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Levetiracetam</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Q40Q9N063P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ACETIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4550K0SC9B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM ACETATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="15"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="44YRR34555" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LEVETIRACETAM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="44YRR34555" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LEVETIRACETAM</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="70860-604-41" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                                    <asContent>
                                       <quantity>
                                          <numerator value="10" unit="1"/>
                                          <denominator value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code code="70860-604-82" codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                       </containerPackagedProduct>
                                       <subjectOf>
                                          <marketingAct>
                                             <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                             <statusCode code="completed"/>
                                             <effectiveTime>
                                                <low value="20180530"/>
                                                <high value="20260331"/>
                                             </effectiveTime>
                                          </marketingAct>
                                       </subjectOf>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA206880" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="completed"/>
                           <effectiveTime>
                              <low value="20180530"/>
                              <high value="20260331"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="s2">
               <id root="34f97a49-2655-18d1-e063-6394a90acaff"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20210519"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%" styleCode="Noautorules">
                           <col width="85.000%" align="left"/>
                           <col width="15.000%" align="left"/>
                           <tbody>
                              <tr>
                                 <td align="left" valign="top">Dosage and Administration (
    
       <linkHtml href="#s9">2.1</linkHtml>)
   
      </td>
                                 <td align="right" valign="top">12/2020</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s3">
               <id root="34f97a49-2656-18d1-e063-6394a90acaff"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <effectiveTime value="20210519"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Levetiracetam in Sodium Chloride Injection is indicated for adjunct therapy in adults (≥16 years of age) with the following seizure types when oral administration is temporarily not feasible:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Partial-onset seizures (
  
     <linkHtml href="#s4">1.1</linkHtml>)
 
    </item>
                           <item>Myoclonic seizures in patients with juvenile myoclonic epilepsy (
  
     <linkHtml href="#s5">1.2</linkHtml>)
 
    </item>
                           <item>Primary generalized tonic-clonic seizures (
  
     <linkHtml href="#s6">1.3</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s4">
                     <id root="34f97a49-2657-18d1-e063-6394a90acaff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 Partial-Onset Seizures</title>
                     <text>
                        <paragraph>Levetiracetam in Sodium Chloride Injection is indicated as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy.</paragraph>
                     </text>
                     <effectiveTime value="20210519"/>
                  </section>
               </component>
               <component>
                  <section ID="s5">
                     <id root="34f97a49-2658-18d1-e063-6394a90acaff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2 Myoclonic Seizures in Patients with Juvenile Myoclonic Epilepsy</title>
                     <text>
                        <paragraph>Levetiracetam in Sodium Chloride Injection is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults with juvenile myoclonic epilepsy.</paragraph>
                     </text>
                     <effectiveTime value="20210519"/>
                  </section>
               </component>
               <component>
                  <section ID="s6">
                     <id root="34f97a49-2659-18d1-e063-6394a90acaff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.3 Primary Generalized Tonic-Clonic Seizures</title>
                     <text>
                        <paragraph>Levetiracetam in Sodium Chloride Injection is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults with idiopathic generalized epilepsy.</paragraph>
                     </text>
                     <effectiveTime value="20210519"/>
                  </section>
               </component>
               <component>
                  <section ID="s7">
                     <id root="34f97a49-265a-18d1-e063-6394a90acaff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.4 Limitations of Use</title>
                     <text>
                        <paragraph>Levetiracetam in Sodium Chloride Injection is an antiepileptic drug indicated for adult patients (16 years and older) when oral administration is temporarily not feasible.</paragraph>
                     </text>
                     <effectiveTime value="20210519"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s8">
               <id root="34f97a49-265b-18d1-e063-6394a90acaff"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20210519"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>For intravenous infusion only (
  
     <linkHtml href="#s9">2.1</linkHtml>)
 
    </item>
                           <item>Do not dilute prior to its use (
  
     <linkHtml href="#s9">2.1</linkHtml>)
 
    </item>
                           <item>Administer dose-specific bag intravenously over 15-minutes (
  
     <linkHtml href="#s9">2.1</linkHtml>)
 
    </item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Initial Exposure to Levetiracetam</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Partial-Onset Seizures:</content>Initial dose is 500 mg twice daily. Increase by 500 mg twice daily every 2 weeks to a maximum recommended dose of 1,500 mg twice daily. (
  
     <linkHtml href="#s10">2.2</linkHtml>)
 
    </item>
                           <item>
                              <content styleCode="italics">Myoclonic Seizures in Patients with Juvenile Myoclonic Epilepsy:</content>Initial dose is 500 mg twice daily. Increase by 500 mg twice daily every 2 weeks to the recommended dose of 1,500 mg twice daily. (
  
     <linkHtml href="#s10">2.2</linkHtml>)
 
    </item>
                           <item>
                              <content styleCode="italics">Primary Generalized Tonic-Clonic Seizures:</content>Initial dose is 500 mg twice daily. Increase by 500 mg twice daily every 2 weeks to the recommended dose of 1,500 mg twice daily. (
  
     <linkHtml href="#s10">2.2</linkHtml>)
 
    </item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Switching from or to oral Levetiracetam</content>: The total daily dosage/frequency of levetiracetam injection should be equivalent to those of oral levetiracetam (
 
    <linkHtml href="#s14">2.3</linkHtml>,
 
    <linkHtml href="#s15">2.4</linkHtml>)

   </paragraph>
                        <paragraph>
                           <content styleCode="underline">Renal Impairment:</content>Dose adjustment necessary based on creatinine clearance (
 
    <linkHtml href="#s16">2.5</linkHtml>) 
    <br/>
                           <br/>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s9">
                     <id root="34f97a49-265c-18d1-e063-6394a90acaff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 General Information – Administration</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Levetiracetam in Sodium Chloride Injection is for intravenous infusion only. It is available in the following concentrations: three single-dose 100 mL bags, each containing a different total dosage of levetiracetam (500 mg [5 mg per mL], 1,000 mg [10 mg per mL], or 1,500 mg [15 mg per mL]).</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">A single-dose bag should be administered intravenously over a 15-minute IV infusion period.</content>
                        </paragraph>
                        <paragraph>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.</paragraph>
                        <paragraph>Levetiracetam in Sodium Chloride Injection should not be further diluted prior to use. Any unused portion of the Levetiracetam in Sodium Chloride Injection contents should be discarded.</paragraph>
                     </text>
                     <effectiveTime value="20210519"/>
                  </section>
               </component>
               <component>
                  <section ID="s10">
                     <id root="34f97a49-265d-18d1-e063-6394a90acaff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Initial Exposure to Levetiracetam</title>
                     <text>
                        <paragraph>Levetiracetam can be initiated with either intravenous or oral administration.</paragraph>
                     </text>
                     <effectiveTime value="20210519"/>
                     <component>
                        <section ID="s11">
                           <id root="34f97a49-265e-18d1-e063-6394a90acaff"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Partial-Onset Seizures</content>
                              </paragraph>
                              <paragraph>In clinical trials of oral levetiracetam, daily doses of 1,000 mg, 2,000 mg, and 3,000 mg, given as twice-daily dosing, were shown to be effective. Although in some studies there was a tendency toward greater response with higher dose
 
  <content styleCode="italics">[see Clinical Studies (
  
   <linkHtml href="#s86">14.1</linkHtml>)]
 
  </content>, a consistent increase in response with increased dose has not been shown.

 </paragraph>
                              <paragraph>Treatment should be initiated with a daily dose of 1,000 mg/day, given as twice-daily dosing (500 mg twice daily). Additional dosing increments may be given (1,000 mg/day additional every 2 weeks) to a maximum recommended daily dose of 3,000 mg. Doses greater than 3,000 mg/day have been used in open-label studies with levetiracetam tablets for periods of 6 months and longer. There is no evidence that doses greater than 3,000 mg/day confer additional benefit.</paragraph>
                           </text>
                           <effectiveTime value="20210519"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s12">
                           <id root="34f97a49-265f-18d1-e063-6394a90acaff"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Myoclonic Seizures in Patients with Juvenile Myoclonic Epilepsy</content>
                              </paragraph>
                              <paragraph>Treatment should be initiated with a dose of 1,000 mg/day, given as twice-daily dosing (500 mg twice daily). Dosage should be increased by 1,000 mg/day every 2 weeks to the recommended daily dose of 3,000 mg. The effectiveness of doses lower than 3,000 mg/day has not been studied.</paragraph>
                           </text>
                           <effectiveTime value="20210519"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s13">
                           <id root="34f97a49-2660-18d1-e063-6394a90acaff"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Primary Generalized Tonic-Clonic Seizures</content>
                              </paragraph>
                              <paragraph>Treatment should be initiated with a dose of 1,000 mg/day, given as twice-daily dosing (500 mg twice daily). Dosage should be increased by 1,000 mg/day every 2 weeks to the recommended daily dose of 3,000 mg. The effectiveness of doses lower than 3,000 mg/day has not been adequately studied.</paragraph>
                           </text>
                           <effectiveTime value="20210519"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s14">
                     <id root="34f97a49-2661-18d1-e063-6394a90acaff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Switching to Intravenous Dosing</title>
                     <text>
                        <paragraph>When switching from oral levetiracetam, the initial total daily intravenous dosage of levetiracetam should be equivalent to the total daily dosage and frequency of oral levetiracetam.</paragraph>
                     </text>
                     <effectiveTime value="20210519"/>
                  </section>
               </component>
               <component>
                  <section ID="s15">
                     <id root="34f97a49-2662-18d1-e063-6394a90acaff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Switching to Oral Dosing</title>
                     <text>
                        <paragraph>At the end of the intravenous treatment period, the patient may be switched to levetiracetam oral administration at the equivalent daily dosage and frequency of the intravenous administration.</paragraph>
                     </text>
                     <effectiveTime value="20210519"/>
                  </section>
               </component>
               <component>
                  <section ID="s16">
                     <id root="34f97a49-2663-18d1-e063-6394a90acaff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Adult Patients with Impaired Renal Function</title>
                     <text>
                        <paragraph>Levetiracetam dosing must be individualized according to the patient's renal function status. Recommended doses and adjustment for dose for adults are shown in
 
  <linkHtml href="#t1">Table 1</linkHtml>. To use this dosing table, an estimate of the patient's creatinine clearance (CLcr) in mL/min is needed.

 </paragraph>
                        <table ID="t1" width="100%">
                           <caption>Table 1: Dosing Adjustment Regimen for Adult Patients with Impaired Renal Function</caption>
                           <col width="37.234%" align="left"/>
                           <col width="19.130%" align="left"/>
                           <col width="20.105%" align="left"/>
                           <col width="23.531%" align="left"/>
                           <tfoot>
                              <tr>
                                 <td colspan="4" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>1</sup>Following dialysis, a 250 mg to 500 mg supplemental dose is recommended.
    
     </paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="left" styleCode="Toprule Botrule Lrule Rrule" valign="middle">
                                    <content styleCode="bold">Group</content>
                                 </td>
                                 <td align="center" styleCode="Toprule Botrule Rrule" valign="middle">
                                    <content styleCode="bold">Creatinine Clearance (mL/min)</content>
                                 </td>
                                 <td align="center" styleCode="Toprule Botrule Rrule" valign="middle">
                                    <content styleCode="bold">Dosage</content>
                                    <br/>
                                    <content styleCode="bold">(mg)</content>
                                 </td>
                                 <td align="center" styleCode="Toprule Botrule Rrule" valign="middle">
                                    <content styleCode="bold">Frequency</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Normal</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">greater than 80</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">500 to 1,500</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">Every 12 hours</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Mild</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">50 to 80</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">500 to 1,000</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">Every 12 hours</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Moderate</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">30 to 50</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">250 to 750</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">Every 12 hours</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Severe</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">less than 30</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">250 to 500</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">Every 12 hours</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">ESRD patients using dialysis</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">----</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">500 to 1,000</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">
                                    <sup>1</sup>Every 24 hours
   
    </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20210519"/>
                  </section>
               </component>
               <component>
                  <section ID="s17">
                     <id root="34f97a49-2664-18d1-e063-6394a90acaff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6 Compatibility with Other Antiepileptic Drugs</title>
                     <text>
                        <paragraph>Levetiracetam in Sodium Chloride Injection is found to be physically compatible and chemically stable for at least 24 hours when mixed with lorazepam, diazepam, and valproate sodium and stored at controlled room temperature 15°C to 30°C (59°F to 86°F).</paragraph>
                        <paragraph>There are no data to support the physical compatibility of levetiracetam injection with antiepileptic drugs that are not listed above.</paragraph>
                     </text>
                     <effectiveTime value="20210519"/>
                  </section>
               </component>
               <component>
                  <section ID="s18">
                     <id root="34f97a49-2665-18d1-e063-6394a90acaff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.7 Discontinuation of Levetiracetam</title>
                     <text>
                        <paragraph>Avoid abrupt withdrawal from levetiracetam in order to reduce the risk of increased seizure frequency and status epilepticus
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#s27">5.6</linkHtml>)].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20210519"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s19">
               <id root="34f97a49-2666-18d1-e063-6394a90acaff"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Injection: Levetiracetam in Sodium Chloride Injection is a clear, colorless solution packaged in a single-dose bag and available in three strengths:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>
                        <content styleCode="bold">500 mg per 100 mL</content>(5 mg per mL): 500 mg levetiracetam in 0.82% sodium chloride
 
  </item>
                     <item>
                        <content styleCode="bold">1,000 mg per 100 mL</content>(10 mg per mL): 1,000 mg levetiracetam in 0.75% sodium chloride
 
  </item>
                     <item>
                        <content styleCode="bold">1,500 mg per 100 mL</content>(15 mg per mL): 1,500 mg levetiracetam in 0.54% sodium chloride
 
  </item>
                  </list>
               </text>
               <effectiveTime value="20210519"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Levetiracetam in Sodium Chloride Injection in single-dose bags:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Levetiracetam in 0.82% sodium chloride (500 mg per 100 mL) (5 mg per mL) (
  
     <linkHtml href="#s19">3</linkHtml>)
 
    </item>
                           <item>Levetiracetam in 0.75% sodium chloride (1,000 mg per 100 mL) (10 mg per mL) (
  
     <linkHtml href="#s19">3</linkHtml>)
 
    </item>
                           <item>Levetiracetam in 0.54% sodium chloride (1,500 mg per 100 mL) (15 mg per mL) (
  
     <linkHtml href="#s19">3</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s20">
               <id root="34f97a49-2667-18d1-e063-6394a90acaff"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Levetiracetam in Sodium Chloride Injection is contraindicated in patients with a hypersensitivity to levetiracetam. Reactions have included anaphylaxis and angioedema
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#s24">5.3</linkHtml>)].
 
  </content>
                  </paragraph>
               </text>
               <effectiveTime value="20210519"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Known hypersensitivity to levetiracetam; angioedema and anaphylaxis have occurred (
  
     <linkHtml href="#s20">4</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s21">
               <id root="34f97a49-2668-18d1-e063-6394a90acaff"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20210519"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Psychiatric Reactions: Behavioral abnormalities including psychotic symptoms, suicidal ideation, irritability, and aggressive behavior have been observed. Monitor patients for psychiatric signs and symptoms (
  
     <linkHtml href="#s22">5.1</linkHtml>)
 
    </item>
                           <item>Somnolence and Fatigue: Monitor patients for these symptoms and advise patients not to drive or operate machinery until they have gained sufficient experience on levetiracetam (
  
     <linkHtml href="#s23">5.2</linkHtml>)
 
    </item>
                           <item>Serious Dermatological Reactions: Discontinue Levetiracetam at the first sign of rash unless clearly not drug related. (
  
     <linkHtml href="#s25">5.4</linkHtml>)
 
    </item>
                           <item>Coordination Difficulties: Monitor for ataxia, abnormal gait, and incoordination. (
  
     <linkHtml href="#s26">5.5</linkHtml>)
 
    </item>
                           <item>Withdrawal Seizures: Levetiracetam must be gradually withdrawn (
  
     <linkHtml href="#s27">5.6</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s22">
                     <id root="34f97a49-2669-18d1-e063-6394a90acaff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Psychiatric Reactions</title>
                     <text>
                        <paragraph>In some patients levetiracetam causes behavioral abnormalities. The incidences of behavioral abnormalities in the myoclonic and primary generalized tonic-clonic seizure studies were comparable to those of the adult partial-onset seizure studies.</paragraph>
                        <paragraph>A total of 13.3% of adult levetiracetam-treated patients compared to 6.2% of placebo patients experienced non- psychotic behavioral symptoms (reported as aggression, agitation, anger, anxiety, apathy, depersonalization, depression, emotional lability, hostility, irritability, and nervousness).</paragraph>
                        <paragraph>A total of 1.7% of adult levetiracetam-treated patients discontinued treatment due to behavioral adverse events, compared to 0.2% of placebo patients. The treatment dose was reduced in 0.8% of adult levetiracetam-treated patients and in 0.5% of placebo patients.</paragraph>
                        <paragraph>One percent of adult levetiracetam-treated patients experienced psychotic symptoms compared to 0.2% of placebo patients.</paragraph>
                        <paragraph>Two (0.3%) adult levetiracetam-treated patients were hospitalized and their treatment was discontinued due to psychosis. Both events, reported as psychosis, developed within the first week of treatment and resolved within 1 to 2 weeks following treatment discontinuation.</paragraph>
                        <paragraph>The above psychiatric signs and symptoms should be monitored.</paragraph>
                     </text>
                     <effectiveTime value="20210519"/>
                  </section>
               </component>
               <component>
                  <section ID="s23">
                     <id root="34f97a49-266a-18d1-e063-6394a90acaff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Somnolence and Fatigue</title>
                     <text>
                        <paragraph>In some patients, levetiracetam causes somnolence and fatigue. The incidences of somnolence and fatigue provided below are from controlled adult partial-onset seizure studies. In general, the incidences of somnolence and fatigue in the myoclonic and primary generalized tonic-clonic studies were comparable to those of the adult partial-onset seizure studies.</paragraph>
                        <paragraph>In controlled trials of adult patients with epilepsy experiencing partial-onset seizures, 14.8% of levetiracetam- treated patients reported somnolence, compared to 8.4% of placebo patients. There was no clear dose response up to 3,000 mg/day. In a study where there was no titration, about 45% of patients receiving 4,000 mg/day reported somnolence. The somnolence was considered serious in 0.3% of the treated patients, compared to 0% in the placebo group. About 3% of levetiracetam-treated patients discontinued treatment due to somnolence, compared to 0.7% of placebo patients. In 1.4% of treated patients and in 0.9% of placebo patients the dose was reduced, while 0.3% of the treated patients were hospitalized due to somnolence.</paragraph>
                        <paragraph>In controlled trials of adult patients with epilepsy experiencing partial-onset seizures, 14.7% of levetiracetam- treated patients reported asthenia, compared to 9.1% of placebo patients. Treatment was discontinued due to asthenia in 0.8% of treated patients as compared to 0.5% of placebo patients. In 0.5% of treated patients and in 0.2% of placebo patients the dose was reduced due to asthenia.</paragraph>
                        <paragraph>Somnolence and asthenia occurred most frequently within the first 4 weeks of treatment.</paragraph>
                        <paragraph>Patients should be monitored for these signs and symptoms and advised not to drive or operate machinery until they have gained sufficient experience on levetiracetam to gauge whether it adversely affects their ability to drive or operate machinery.</paragraph>
                     </text>
                     <effectiveTime value="20210519"/>
                  </section>
               </component>
               <component>
                  <section ID="s24">
                     <id root="34f97a49-266b-18d1-e063-6394a90acaff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Anaphylaxis and Angioedema</title>
                     <text>
                        <paragraph>Levetiracetam can cause anaphylaxis or angioedema after the first dose or at any time during treatment. Signs and symptoms in cases reported in the postmarketing setting with levetiracetam have included hypotension, hives, rash, respiratory distress, and swelling of the face, lip, mouth, eye, tongue, throat, and feet. In some reported cases, reactions were life-threatening and required emergency treatment. If a patient develops signs or symptoms of anaphylaxis or angioedema, levetiracetam should be discontinued and the patient should seek immediate medical attention. Levetiracetam should be discontinued permanently if a clear alternative etiology for the reaction cannot be established
 
  <content styleCode="italics">[see Contraindications (
  
   <linkHtml href="#s20">4</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20210519"/>
                  </section>
               </component>
               <component>
                  <section ID="s25">
                     <id root="34f97a49-266c-18d1-e063-6394a90acaff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Serious Dermatological Reactions</title>
                     <text>
                        <paragraph>Serious dermatological reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported in patients treated with levetiracetam. The median time of onset is reported to be 14 to 17 days, but cases have been reported at least four months after initiation of treatment. Recurrence of the serious skin reactions following rechallenge with levetiracetam has also been reported. Levetiracetam should be discontinued at the first sign of a rash, unless the rash is clearly not drug-related. If signs or symptoms suggest SJS/TEN, use of this drug should not be resumed and alternative therapy should be considered.</paragraph>
                     </text>
                     <effectiveTime value="20210519"/>
                  </section>
               </component>
               <component>
                  <section ID="s26">
                     <id root="34f97a49-266d-18d1-e063-6394a90acaff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Coordination Difficulties</title>
                     <text>
                        <paragraph>Coordination difficulties were only observed in the adult partial-onset seizure studies. A total of 3.4% of adult levetiracetam-treated patients experienced coordination difficulties, (reported as either ataxia, abnormal gait, or incoordination) compared to 1.6% of placebo patients. A total of 0.4% of patients in controlled trials discontinued levetiracetam treatment due to ataxia, compared to 0% of placebo patients. In 0.7% of treated patients and in 0.2% of placebo patients the dose was reduced due to coordination difficulties, while one of the treated patients was hospitalized due to worsening of pre-existing ataxia. These events occurred most frequently within the first 4 weeks of treatment.</paragraph>
                        <paragraph>Patients should be monitored for these signs and symptoms and advised not to drive or operate machinery until they have gained sufficient experience on levetiracetam to gauge whether it adversely affects their ability to drive or operate machinery.</paragraph>
                     </text>
                     <effectiveTime value="20210519"/>
                  </section>
               </component>
               <component>
                  <section ID="s27">
                     <id root="34f97a49-266e-18d1-e063-6394a90acaff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Withdrawal Seizures</title>
                     <text>
                        <paragraph>As with most antiepileptic drugs, levetiracetam should be withdrawn gradually because of the risk of increased seizure frequency and status epilepticus. But if withdrawal is needed because of a serious adverse reaction, rapid discontinuation can be considered.</paragraph>
                     </text>
                     <effectiveTime value="20210519"/>
                  </section>
               </component>
               <component>
                  <section ID="s28">
                     <id root="34f97a49-266f-18d1-e063-6394a90acaff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Hematologic Abnormalities</title>
                     <text>
                        <paragraph>Levetiracetam can cause hematologic abnormalities. Hematologic abnormalities occurred in clinical trials and included decreases in white blood cell (WBC), neutrophil, and red blood cell counts (RBC); decreases in hemoglobin and hematocrit; and increases in eosinophil counts. Cases of agranulocytosis, pancytopenia, and thrombocytopenia have been reported in the postmarketing setting. A complete blood count is recommended in patients experiencing significant weakness, pyrexia, recurrent infections, or coagulation disorders.</paragraph>
                     </text>
                     <effectiveTime value="20210519"/>
                     <component>
                        <section ID="s29">
                           <id root="34f97a49-2670-18d1-e063-6394a90acaff"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Partial-Onset Seizures</content>
                              </paragraph>
                              <paragraph>In controlled clinical studies using an oral formulation of levetiracetam in adult patients with partial-onset seizures, minor but statistically significant decreases compared to placebo in total mean RBC (0.03 × 10
 
  <sup>6</sup>/mm
 
  <sup>3</sup>), mean hemoglobin (0.09 g/dL), and mean hematocrit (0.38%), were seen in levetiracetam-treated patients.

 </paragraph>
                              <paragraph>A total of 3.2% of levetiracetam-treated and 1.8% of placebo-treated patients had at least one possibly significant (≤2.8 × 10
 
  <sup>9</sup>/L) decreased WBC, and 2.4% of levetiracetam-treated and 1.4% of placebo-treated patients had at least one possibly significant (≤1.0 × 10
 
  <sup>9</sup>/L) decreased neutrophil count. Of the levetiracetam-treated patients with a low neutrophil count, all but one rose towards or to baseline with continued treatment. No patient was discontinued secondary to low neutrophil counts.

 </paragraph>
                           </text>
                           <effectiveTime value="20210519"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s30">
                           <id root="34f97a49-2671-18d1-e063-6394a90acaff"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Juvenile Myoclonic Epilepsy</content>
                              </paragraph>
                              <paragraph>Although there were no obvious hematologic abnormalities observed in patients with JME, the limited number of patients makes any conclusion tentative. The data from the partial seizure patients should be considered to be relevant for JME patients.</paragraph>
                           </text>
                           <effectiveTime value="20210519"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s31">
                     <id root="34f97a49-2672-18d1-e063-6394a90acaff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Seizure Control During Pregnancy</title>
                     <text>
                        <paragraph>Physiological changes may gradually decrease plasma levels of levetiracetam throughout pregnancy. This decrease is more pronounced during the third trimester. It is recommended that patients be monitored carefully during pregnancy. Close monitoring should continue through the postpartum period especially if the dose was changed during pregnancy.</paragraph>
                     </text>
                     <effectiveTime value="20210519"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s32">
               <id root="34f97a49-2673-18d1-e063-6394a90acaff"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following serious adverse reactions are discussed in more details in other sections of labeling:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Psychiatric Reactions
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#s22">5.1</linkHtml>)]
  
   </content>
                     </item>
                     <item>Somnolence and Fatigue
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#s23">5.2</linkHtml>)]
  
   </content>
                     </item>
                     <item>Anaphylaxis and Angioedema
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#s24">5.3</linkHtml>)]
  
   </content>
                     </item>
                     <item>Serious Dermatological Reactions
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#s25">5.4</linkHtml>)]
  
   </content>
                     </item>
                     <item>Coordination Difficulties
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#s26">5.5</linkHtml>)]
  
   </content>
                     </item>
                     <item>Withdrawal Seizures
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#s27">5.6</linkHtml>)]
  
   </content>
                     </item>
                     <item>Hematologic Abnormalities
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#s28">5.7</linkHtml>)]
  
   </content>
                     </item>
                     <item>Seizure Control During Pregnancy
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#s31">5.8</linkHtml>)]
  
   </content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20210519"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Most common adverse reactions (incidence in levetiracetam-treated patients is ≥5% more than in placebo-treated patients) include: somnolence, asthenia, infection, and dizziness (
  
     <linkHtml href="#s33">6.1</linkHtml>)
 
    </item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Athenex Pharmaceutical Division, LLC. at 1-855-273-0154 or FDA at 1-800-FDA-1088 or</content>
                           <content styleCode="bold">
                              <content styleCode="underline">www.fda.gov/medwatch</content>
                           </content>
                           <content styleCode="bold">.</content>
                           <br/>
                           <br/>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s33">
                     <id root="34f97a49-2674-18d1-e063-6394a90acaff"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The adverse reactions that result from levetiracetam injection use include all of those reported for levetiracetam tablets and oral solution. Equivalent doses of intravenous (IV) levetiracetam and oral levetiracetam result in equivalent C
 
  <sub>max</sub>, C
 
  <sub>min</sub>, and total systemic exposure to levetiracetam when the IV levetiracetam is administered as a 15-minute infusion.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Partial-Onset Seizures</content>
                        </paragraph>
                        <paragraph>In controlled clinical studies using levetiracetam tablets in adults with partial-onset seizures
 
  <content styleCode="italics">[see Clinical Studies (
  
   <linkHtml href="#s86">14.1</linkHtml>)]
 
  </content>, the most common adverse reactions in adult patients receiving levetiracetam in combination with other AEDs, for events with rates greater than placebo, were somnolence, asthenia, infection and dizziness.

 </paragraph>
                        <paragraph>Of the most common adverse reactions in adults experiencing partial-onset seizures, asthenia, somnolence and dizziness occurred predominantly during the first 4 weeks of treatment with levetiracetam.</paragraph>
                        <paragraph>
                           <linkHtml href="#t2">Table 2</linkHtml>lists adverse reactions that occurred in at least 1% of adult epilepsy patients receiving levetiracetam tablets in placebo-controlled studies and were numerically more common than in patients treated with placebo. In these studies, either levetiracetam or placebo was added to concurrent AED therapy. Adverse reactions were usually mild to moderate in intensity.

 </paragraph>
                        <table ID="t2" width="100%">
                           <caption>Table 2: Adverse Reactions* In Placebo-Controlled, Adjunctive Studies In Adults Experiencing Partial-Onset Seizures</caption>
                           <col width="44.533%" align="left"/>
                           <col width="29.433%" align="left"/>
                           <col width="26.033%" align="left"/>
                           <tfoot>
                              <tr>
                                 <td colspan="3" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <content styleCode="bold">*</content>Adverse reactions occurred in at least 1% of levetiracetam-treated patients and occurred more frequently than placebo-treated patients
    
     </paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="left" styleCode="Toprule Botrule Lrule Rrule" valign="middle">
                                    <content styleCode="bold">Adverse Reaction</content>
                                 </td>
                                 <td align="center" styleCode="Toprule Botrule Rrule" valign="middle">
                                    <content styleCode="bold">Levetiracetam 
      <br/>  (N=769)
     </content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                 </td>
                                 <td align="center" styleCode="Toprule Botrule Rrule" valign="middle">
                                    <content styleCode="bold">Placebo</content>
                                    <br/>
                                    <content styleCode="bold">(N=439)</content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Asthenia</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">15</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">9</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Somnolence</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">15</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">8</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Headache</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">14</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">13</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Infection</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">13</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">8</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Dizziness</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">9</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">4</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Pain</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">7</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">6</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Pharyngitis</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">6</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">4</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Depression</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">4</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">2</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Nervousness</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">4</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">2</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Rhinitis</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">4</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">3</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Anorexia</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">3</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">2</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Ataxia</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">3</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">1</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Vertigo</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">3</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">1</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Amnesia</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">2</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">1</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Anxiety</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">2</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">1</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Cough Increased</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">2</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">1</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Diplopia</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">2</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">1</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Emotional Lability</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">2</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">0</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Hostility</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">2</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">1</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Paresthesia</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">2</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">1</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Sinusitis</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">2</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">1</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In controlled adult clinical studies using levetiracetam tablets, 15% of patients receiving levetiracetam and 12% receiving placebo either discontinued or had a dose reduction as a result of an adverse reaction.
 
  <linkHtml href="#t3">Table 3</linkHtml>lists the most common (&gt;1%) adverse reactions that resulted in discontinuation or dose reduction and that occurred more frequently in levetiracetam-treated patients than in placebo-treated patients.

 </paragraph>
                        <table ID="t3" width="100%">
                           <caption>Table 3: Adverse Reactions that Resulted in Discontinuation or Dose Reduction in Placebo-Controlled Studies in Adults Experiencing Partial-Onset Seizures</caption>
                           <col width="34.912%" align="left"/>
                           <col width="40.714%" align="left"/>
                           <col width="24.375%" align="left"/>
                           <tbody>
                              <tr>
                                 <td align="left" styleCode="Toprule Botrule Lrule Rrule" valign="middle">
                                    <content styleCode="bold">Adverse Reaction</content>
                                 </td>
                                 <td align="center" styleCode="Toprule Botrule Rrule" valign="middle">
                                    <content styleCode="bold">Levetiracetam</content>
                                    <br/>
                                    <content styleCode="bold">(N=769)</content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                 </td>
                                 <td align="center" styleCode="Toprule Botrule Rrule" valign="middle">
                                    <content styleCode="bold">Placebo 
      <br/>  (N=439)
     </content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Somnolence</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">4</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">2</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Dizziness</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">1</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">0</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20210519"/>
                     <component>
                        <section ID="s34">
                           <id root="34f97a49-2675-18d1-e063-6394a90acaff"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Myoclonic Seizures</content>
                              </paragraph>
                              <paragraph>Although the pattern of adverse reactions in this study seems somewhat different from that seen in patients with partial seizures, this is likely due to the much smaller number of patients in this study compared to partial seizure studies. The adverse reaction pattern for patients with JME is expected to be essentially the same as for patients with partial seizures.</paragraph>
                              <paragraph>In the controlled clinical study using levetiracetam tablets in patients with myoclonic seizures, the most common adverse reactions in patients using levetiracetam in combination with other AEDs, for events with rates greater than placebo, were somnolence, neck pain, and pharyngitis.</paragraph>
                              <paragraph>
                                 <linkHtml href="#t4">Table 4</linkHtml>lists adverse reactions that occurred in at least 5% of juvenile myoclonic epilepsy patients experiencing myoclonic seizures treated with levetiracetam tablets and were numerically more common than in patients treated with placebo. In this study, either levetiracetam or placebo was added to concurrent AED therapy. Adverse reactions were usually mild to moderate in intensity.

 </paragraph>
                              <table ID="t4" width="100%">
                                 <caption>Table 4: Adverse Reactions* in a Placebo-Controlled, Adjunctive Study in Patients 12 Years of Age and Older with Myoclonic Seizures</caption>
                                 <col width="51.933%" align="left"/>
                                 <col width="25.833%" align="left"/>
                                 <col width="22.233%" align="left"/>
                                 <tfoot>
                                    <tr>
                                       <td colspan="3" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <content styleCode="bold">*</content>Adverse reactions occurred in at least 5% of levetiracetam-treated patients and occurred more frequently than placebo-treated patients
    
     </paragraph>
                                       </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td align="left" styleCode="Toprule Botrule Lrule Rrule" valign="middle">
                                          <content styleCode="bold">Adverse Reaction</content>
                                       </td>
                                       <td align="center" styleCode="Toprule Botrule Rrule" valign="middle">
                                          <content styleCode="bold">Levetiracetam 
      <br/>  (N=60)
     </content>
                                          <br/>
                                          <content styleCode="bold">%</content>
                                       </td>
                                       <td align="center" styleCode="Toprule Botrule Rrule" valign="middle">
                                          <content styleCode="bold">Placebo</content>
                                          <br/>
                                          <content styleCode="bold">(N=60)</content>
                                          <br/>
                                          <content styleCode="bold">%</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Somnolence</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">12</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">2</td>
                                    </tr>
                                    <tr>
                                       <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Neck pain</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">8</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">2</td>
                                    </tr>
                                    <tr>
                                       <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Pharyngitis</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">7</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">0</td>
                                    </tr>
                                    <tr>
                                       <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Depression</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">5</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">2</td>
                                    </tr>
                                    <tr>
                                       <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Influenza</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">5</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">2</td>
                                    </tr>
                                    <tr>
                                       <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Vertigo</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">5</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">3</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>In the placebo-controlled study using levetiracetam tablets in patients with JME, 8% of patients receiving levetiracetam and 2% receiving placebo either discontinued or had a dose reduction as a result of an adverse reaction. The adverse reactions that led to discontinuation or dose reduction and that occurred more frequently in levetiracetam-treated patients than in placebo-treated patients are presented in
 
  <linkHtml href="#t5">Table 5</linkHtml>.

 </paragraph>
                              <table ID="t5" width="100%">
                                 <caption>Table 5: Adverse Reactions that Resulted in Discontinuation or Dose Reduction in Patients with Juvenile Myoclonic Epilepsy</caption>
                                 <col width="32.867%" align="left"/>
                                 <col width="36.733%" align="left"/>
                                 <col width="30.400%" align="left"/>
                                 <tbody>
                                    <tr>
                                       <td align="left" styleCode="Toprule Botrule Lrule Rrule" valign="top">
                                          <br/>
                                          <content styleCode="bold">Adverse Reaction</content>
                                       </td>
                                       <td align="center" styleCode="Toprule Botrule Rrule" valign="top">
                                          <content styleCode="bold">Levetiracetam</content>
                                          <br/>
                                          <content styleCode="bold">(N=60)</content>
                                          <br/>
                                          <content styleCode="bold">%</content>
                                       </td>
                                       <td align="center" styleCode="Toprule Botrule Rrule" valign="top">
                                          <content styleCode="bold">Placebo</content>
                                          <br/>
                                          <content styleCode="bold">(N=60)</content>
                                          <br/>
                                          <content styleCode="bold">%</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Anxiety</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">3</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">2</td>
                                    </tr>
                                    <tr>
                                       <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Depressed mood</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">2</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">0</td>
                                    </tr>
                                    <tr>
                                       <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Depression</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">2</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">0</td>
                                    </tr>
                                    <tr>
                                       <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Diplopia</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">2</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">0</td>
                                    </tr>
                                    <tr>
                                       <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Hypersomnia</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">2</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">0</td>
                                    </tr>
                                    <tr>
                                       <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Insomnia</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">2</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">0</td>
                                    </tr>
                                    <tr>
                                       <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Irritability</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">2</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">0</td>
                                    </tr>
                                    <tr>
                                       <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Nervousness</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">2</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">0</td>
                                    </tr>
                                    <tr>
                                       <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Somnolence</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">2</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">0</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20210519"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s35">
                           <id root="34f97a49-2676-18d1-e063-6394a90acaff"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Primary Generalized Tonic-Clonic Seizures</content>
                              </paragraph>
                              <paragraph>Although the pattern of adverse reactions in this study seems somewhat different from that seen in patients with partial seizures, this is likely due to the much smaller number of patients in this study compared to partial seizure studies. The adverse reaction pattern for patients with primary generalized tonic-clonic (PGTC) seizures is expected to be essentially the same as for patients with partial seizures.</paragraph>
                              <paragraph>In the controlled clinical study that included patients with PGTC seizures, the most common adverse reaction in patients receiving levetiracetam oral formulation in combination with other AEDs, for events with rates greater than placebo was nasopharyngitis.</paragraph>
                              <paragraph>
                                 <linkHtml href="#t6">Table 6</linkHtml>lists adverse reactions that occurred in at least 5% of idiopathic generalized epilepsy patients experiencing PGTC seizures treated with levetiracetam and were numerically more common than in patients treated with placebo. In this study, either levetiracetam or placebo was added to concurrent AED therapy.

 </paragraph>
                              <table ID="t6" width="100%">
                                 <caption>Table 6: Adverse Reactions* in a Placebo-Controlled, Adjunctive Study in Patients with PGTC Seizures</caption>
                                 <col width="47.084%" align="left"/>
                                 <col width="26.491%" align="left"/>
                                 <col width="26.425%" align="left"/>
                                 <tfoot>
                                    <tr>
                                       <td colspan="3" align="left" valign="top">
                                          <paragraph styleCode="footnote">* Adverse reactions occurred in at least 5% of levetiracetam-treated patients and occurred more frequently than placebo-treated patients</paragraph>
                                       </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td align="left" styleCode="Toprule Botrule Lrule Rrule" valign="top">
                                          <br/>
                                          <content styleCode="bold">Adverse Reaction</content>
                                       </td>
                                       <td align="center" styleCode="Toprule Botrule Rrule" valign="top">
                                          <content styleCode="bold">Levetiracetam 
      <br/>  (N=79)
     </content>
                                          <br/>
                                          <content styleCode="bold">%</content>
                                       </td>
                                       <td align="center" styleCode="Toprule Botrule Rrule" valign="top">
                                          <content styleCode="bold">Placebo</content>
                                          <br/>
                                          <content styleCode="bold">(N=84)</content>
                                          <br/>
                                          <content styleCode="bold">%</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Nasopharyngitis</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">14</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">5</td>
                                    </tr>
                                    <tr>
                                       <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Fatigue</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">10</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">8</td>
                                    </tr>
                                    <tr>
                                       <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Diarrhea</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">8</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">7</td>
                                    </tr>
                                    <tr>
                                       <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Irritability</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">6</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">2</td>
                                    </tr>
                                    <tr>
                                       <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Mood swings</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">5</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="top">1</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>In the placebo-controlled study, 5% of patients receiving levetiracetam and 8% receiving placebo either discontinued or had a dose reduction during the treatment period as a result of an adverse reaction.</paragraph>
                              <paragraph>This study was too small to adequately characterize the adverse reactions that could be expected to result in discontinuation of treatment in this population. It is expected that the adverse reactions that would lead to discontinuation in this population would be similar to those resulting in discontinuation in other epilepsy trials (see
 
  <linkHtml href="#t3">Tables 3</linkHtml>and
 
  <linkHtml href="#t5">5</linkHtml>).

 </paragraph>
                              <paragraph>In addition, the following adverse reactions were seen in other controlled adult studies of levetiracetam: balance disorder, disturbance in attention, eczema, memory impairment, myalgia, and blurred vision.</paragraph>
                           </text>
                           <effectiveTime value="20210519"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s36">
                           <id root="34f97a49-2677-18d1-e063-6394a90acaff"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Comparison of Gender, Age and Race</content>
                              </paragraph>
                              <paragraph>The overall adverse reaction profile of levetiracetam was similar between females and males. There are insufficient data to support a statement regarding the distribution of adverse reactions by age and race.</paragraph>
                           </text>
                           <effectiveTime value="20210519"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s37">
                     <id root="34f97a49-2678-18d1-e063-6394a90acaff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post-approval use of levetiracetam. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>In addition to the adverse reactions listed above
 
  <content styleCode="italics">[see Adverse Reactions (
  
   <linkHtml href="#s33">6.1</linkHtml>)]
 
  </content>, the following adverse reactions have been reported in patients receiving marketed levetiracetam worldwide. The listing is alphabetized: abnormal liver function test, acute kidney injury, agranulocytosis, anaphylaxis, angioedema, choreoathetosis, drug reaction with eosinophilia and systemic symptoms (DRESS), dyskinesia, erythema multiforme, hepatic failure, hepatitis, hyponatremia, muscular weakness, pancreatitis, pancytopenia (with bone marrow suppression identified in some of these cases), panic attack, thrombocytopenia, weight loss, and worsening of seizures. Alopecia has been reported with levetiracetam use; recovery was observed in majority of cases where levetiracetam was discontinued.

 </paragraph>
                     </text>
                     <effectiveTime value="20210519"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s38">
               <id root="34f97a49-2679-18d1-e063-6394a90acaff"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20210519"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Pregnancy: Plasma levels of levetiracetam may be decreased; monitor closely during pregnancy. Based on animal data, may cause fetal harm. (
  
     <linkHtml href="#s31">5.8</linkHtml>,
  
     <linkHtml href="#s39">8.1</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s39">
                     <id root="34f97a49-267a-18d1-e063-6394a90acaff"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20210519"/>
                     <component>
                        <section ID="s40">
                           <id root="34f97a49-267b-18d1-e063-6394a90acaff"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pregnancy Exposure Registry</content>
                              </paragraph>
                              <paragraph>There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (AEDs), including levetiracetam, during pregnancy. Encourage women who are taking levetiracetam injection during pregnancy to enroll in the North American Antiepileptic Drug (NAAED) pregnancy registry by calling 1-888-233-2334 or visiting
 
  <content styleCode="underline">http://www.aedpregnancyregistry.org/</content>.

 </paragraph>
                           </text>
                           <effectiveTime value="20210519"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s41">
                           <id root="34f97a49-267c-18d1-e063-6394a90acaff"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Prolonged experience with levetiracetam in pregnant women has not identified a drug-associated risk of major birth defects or miscarriage, based on published literature, which includes data from pregnancy registries and reflects experience over two decades
 
  <content styleCode="italics">[see
  
   <linkHtml href="#s44">Human Data</linkHtml>].
 
  </content>In animal studies, levetiracetam produced developmental toxicity (increased embryofetal and offspring mortality, increased incidences of fetal structural abnormalities, decreased embryofetal and offspring growth, neurobehavioral alterations in offspring) at doses similar to human therapeutic doses
 
  <content styleCode="italics">[see
  
   <linkHtml href="#s45">Animal Data</linkHtml>].
 
  </content>
                              </paragraph>
                              <paragraph>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown.</paragraph>
                           </text>
                           <effectiveTime value="20210519"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s42">
                           <id root="34f97a49-267d-18d1-e063-6394a90acaff"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                              <paragraph>Levetiracetam blood levels may decrease during pregnancy
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#s31">5.8</linkHtml>)].
 
  </content>
                              </paragraph>
                              <paragraph>Physiological changes during pregnancy may affect levetiracetam concentration. Decrease in levetiracetam plasma concentrations has been observed during pregnancy. This decrease is more pronounced during the third trimester. Dose adjustments may be necessary to maintain clinical response.</paragraph>
                           </text>
                           <effectiveTime value="20210519"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s43">
                           <id root="34f97a49-267e-18d1-e063-6394a90acaff"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20210519"/>
                           <component>
                              <section ID="s44">
                                 <id root="34f97a49-267f-18d1-e063-6394a90acaff"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Human Data</content>
                                    </paragraph>
                                    <paragraph>While available studies cannot definitively establish the absence of risk, data from the published literature and pregnancy registries have not established an association with levetiracetam use during pregnancy and major birth defects or miscarriage.</paragraph>
                                 </text>
                                 <effectiveTime value="20210519"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s45">
                                 <id root="34f97a49-2680-18d1-e063-6394a90acaff"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>When levetiracetam (0, 400, 1,200, or 3,600 mg/kg/day) was administered orally to pregnant rats during the period of organogenesis, reduced fetal weights and increased incidence of fetal skeletal variations were observed at the highest dose tested. There was no evidence of maternal toxicity. The no-effect dose for adverse effects on embryofetal development in rats (1,200 mg/kg/day) is approximately 4 times the maximum recommended human dose (MRHD) of 3,000 mg on a body surface area (mg/m
 
  <sup>2</sup>) basis.

 </paragraph>
                                    <paragraph>Oral administration of levetiracetam (0, 200, 600, or 1,800 mg/kg/day) to pregnant rabbits during the period of organogenesis resulted in increased embryofetal mortality and incidence of fetal skeletal variations at the mid and high dose and decreased fetal weights and increased incidence of fetal malformations at the high dose, which was associated with maternal toxicity. The no-effect dose for adverse effects on embryofetal development in rabbits (200 mg/kg/day) is approximately equivalent to the MRHD on a mg/m
 
  <sup>2</sup>basis.

 </paragraph>
                                    <paragraph>Oral administration of levetiracetam (0, 70, 350, or 1,800 mg/kg/day) to female rats throughout pregnancy and lactation led to an increased incidence of fetal skeletal variations, reduced fetal body weight, and decreased growth in offspring at the mid and high doses and increased pup mortality and neurobehavioral alterations in offspring at the highest dose tested. There was no evidence of maternal toxicity. The no-effect dose for adverse effects on pre- and post-natal development in rats (70 mg/kg/day) is less than the MRHD on a mg/m
 
  <sup>2</sup>basis

 </paragraph>
                                    <paragraph>Oral administration of levetiracetam to rats during the latter part of gestation and throughout lactation produced no adverse developmental or maternal effects at doses of up to 1,800 mg/kg/day (6 times the MRHD on a mg/m
 
  <sup>2</sup>basis).

 </paragraph>
                                 </text>
                                 <effectiveTime value="20210519"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s46">
                     <id root="34f97a49-2681-18d1-e063-6394a90acaff"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20210519"/>
                     <component>
                        <section ID="s47">
                           <id root="34f97a49-2682-18d1-e063-6394a90acaff"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Levetiracetam is excreted in human milk. There are no data on the effects of levetiracetam on the breastfed infant, or the effects on milk production.</paragraph>
                              <paragraph>The development and health benefits of breastfeeding should be considered along with the mother's clinical need for levetiracetam and any potential adverse effects on the breastfed infant from levetiracetam or from the underlying maternal condition.</paragraph>
                           </text>
                           <effectiveTime value="20210519"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s48">
                     <id root="34f97a49-2683-18d1-e063-6394a90acaff"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness of levetiracetam injection in patients below the age of 16 years have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20210519"/>
                  </section>
               </component>
               <component>
                  <section ID="s49">
                     <id root="34f97a49-2684-18d1-e063-6394a90acaff"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>There were 347 subjects in clinical studies of levetiracetam that were 65 years old and over. No overall differences in safety were observed between these subjects and younger subjects. There were insufficient numbers of elderly subjects in controlled trials of epilepsy to adequately assess the effectiveness of levetiracetam in these patients.</paragraph>
                        <paragraph>Levetiracetam is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function
 
  <content styleCode="italics">[see Clinical Pharmacology (
  
   <linkHtml href="#s60">12.3</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20210519"/>
                  </section>
               </component>
               <component>
                  <section ID="s50">
                     <id root="34f97a49-2685-18d1-e063-6394a90acaff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph>Clearance of levetiracetam is decreased in patients with renal impairment and is correlated with creatinine clearance
 
  <content styleCode="italics">[see Clinical Pharmacology (
  
   <linkHtml href="#s60">12.3</linkHtml>)]
 
  </content>. Dosage adjustment is recommended for patients with impaired renal function and supplemental doses should be given to patients after dialysis
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#s16">2.5</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20210519"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s51">
               <id root="34f97a49-2686-18d1-e063-6394a90acaff"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <effectiveTime value="20210519"/>
               <component>
                  <section ID="s52">
                     <id root="34f97a49-2687-18d1-e063-6394a90acaff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>10.1 Signs, Symptoms and Laboratory Findings of Acute Overdosage in Humans</title>
                     <text>
                        <paragraph>The highest known dose of oral levetiracetam received in the clinical development program was 6,000 mg/day. Other than drowsiness, there were no adverse reactions in the few known cases of overdose in clinical trials. Cases of somnolence, agitation, aggression, depressed level of consciousness, respiratory depression and coma were observed with levetiracetam overdoses in postmarketing use.</paragraph>
                     </text>
                     <effectiveTime value="20210519"/>
                  </section>
               </component>
               <component>
                  <section ID="s53">
                     <id root="34f97a49-2688-18d1-e063-6394a90acaff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>10.2 Management of Overdose</title>
                     <text>
                        <paragraph>There is no specific antidote for overdose with levetiracetam. If indicated, elimination of unabsorbed drug should be attempted by emesis or gastric lavage; usual precautions should be observed to maintain airway. General supportive care of the patient is indicated including monitoring of vital signs and observation of the patient's clinical status. A Certified Poison Control Center should be contacted for up to date information on the management of overdose with levetiracetam.</paragraph>
                     </text>
                     <effectiveTime value="20210519"/>
                  </section>
               </component>
               <component>
                  <section ID="s54">
                     <id root="34f97a49-2689-18d1-e063-6394a90acaff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>10.3 Hemodialysis</title>
                     <text>
                        <paragraph>Standard hemodialysis procedures result in significant clearance of levetiracetam (approximately 50% in 4 hours) and should be considered in cases of overdose. Although hemodialysis has not been performed in the few known cases of overdose, it may be indicated by the patient's clinical state or in patients with significant renal impairment.</paragraph>
                     </text>
                     <effectiveTime value="20210519"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s55">
               <id root="34f97a49-268a-18d1-e063-6394a90acaff"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Levetiracetam in Sodium Chloride Injection is an antiepileptic drug available as a clear, colorless, sterile solution for intravenous administration.</paragraph>
                  <paragraph>The chemical name of levetiracetam, a single enantiomer, is (-)-(S)-α-ethyl-2-oxo-1-pyrrolidine acetamide, its molecular formula is C
 
  <sub>8</sub>H
 
  <sub>14</sub>N
 
  <sub>2</sub>O
 
  <sub>2</sub>and its molecular weight is 170.21. Levetiracetam is chemically unrelated to existing antiepileptic drugs (AEDs). It has the following structural formula:

 </paragraph>
                  <renderMultiMedia ID="f01" referencedObject="mm01"/>
                  <paragraph>Levetiracetam is a white to off-white crystalline powder with a faint odor and a bitter taste. It is very soluble in water (104.0 g/100 mL). It is freely soluble in chloroform (65.3 g/100 mL) and in methanol (53.6 g/100 mL), soluble in ethanol (16.5 g/100 mL), sparingly soluble in acetonitrile (5.7 g/100 mL) and practically insoluble in n-hexane. (Solubility limits are expressed as g/100 mL solvent.)</paragraph>
                  <paragraph>Levetiracetam in Sodium Chloride Injection is a clear, colorless, sterile solution that is available in a single-dose dual port bag with an aluminum overwrap. The container closure is not made with natural rubber latex.</paragraph>
                  <paragraph>
                     <content styleCode="bold">500 mg per 100 mL:</content>One 100 mL bag contains 500 mg of levetiracetam (5 mg per mL), water for injection, 820 mg sodium chloride, 5.5 mg of glacial acetic acid and buffered at approximately pH 5.5 with glacial acetic acid and 164 mg sodium acetate trihydrate.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">1,000 mg per 100 mL:</content>One 100 mL bag contains 1,000 mg of levetiracetam (10 mg per mL), water for injection, 750 mg sodium chloride, 6.5 mg of glacial acetic acid and buffered at approximately pH 5.5 with glacial acetic acid and 164 mg sodium acetate trihydrate.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">1,500 mg per 100 mL:</content>One 100 mL bag contains 1,500 mg of levetiracetam (15 mg per mL), water for injection, 540 mg sodium chloride, 7.5 mg of glacial acetic acid and buffered at approximately pH 5.5 with glacial acetic acid and 164 mg sodium acetate trihydrate.

 </paragraph>
               </text>
               <effectiveTime value="20210519"/>
               <component>
                  <observationMedia ID="mm01">
                     <text>structural formula
</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="lev18-0003-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s56">
               <id root="34f97a49-268b-18d1-e063-6394a90acaff"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20210519"/>
               <component>
                  <section ID="s57">
                     <id root="34f97a49-268c-18d1-e063-6394a90acaff"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>The precise mechanism(s) by which levetiracetam exerts its antiepileptic effect is unknown.</paragraph>
                        <paragraph>A saturable and stereoselective neuronal binding site in rat brain tissue has been described for levetiracetam. Experimental data indicate that this binding site is the synaptic vesicle protein SV2A, thought to be involved in the regulation of vesicle exocytosis. Although the molecular significance of levetiracetam binding to synaptic vesicle protein SV2A is not understood, levetiracetam and related analogs showed a rank order of affinity for SV2A which correlated with the potency of their antiseizure activity in audiogenic seizure-prone mice. These findings suggest that the interaction of levetiracetam with the SV2A protein may contribute to the antiepileptic mechanism of action of the drug.</paragraph>
                     </text>
                     <effectiveTime value="20210519"/>
                  </section>
               </component>
               <component>
                  <section ID="s58">
                     <id root="34f97a49-268d-18d1-e063-6394a90acaff"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <effectiveTime value="20210519"/>
                     <component>
                        <section ID="s59">
                           <id root="34f97a49-268e-18d1-e063-6394a90acaff"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Effects on QTc Interval</content>
                              </paragraph>
                              <paragraph>The effect of levetiracetam on QTc prolongation was evaluated in a randomized, double-blind, positive-controlled (moxifloxacin 400 mg) and placebo-controlled crossover study of levetiracetam (1,000 mg or 5,000 mg) in 52 healthy subjects. The upper bound of the 90% confidence interval for the largest placebo-adjusted, baseline-corrected QTc was below 10 milliseconds. Therefore, there was no evidence of significant QTc prolongation in this study.</paragraph>
                           </text>
                           <effectiveTime value="20210519"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s60">
                     <id root="34f97a49-268f-18d1-e063-6394a90acaff"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Equivalent doses of intravenous (IV) levetiracetam and oral levetiracetam result in equivalent C
 
  <sub>max</sub>, C
 
  <sub>min</sub>, and total systemic exposure to levetiracetam when the IV levetiracetam is administered as a 15 minute infusion.

 </paragraph>
                     </text>
                     <effectiveTime value="20210519"/>
                     <component>
                        <section ID="s61">
                           <id root="34f97a49-2690-18d1-e063-6394a90acaff"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Overview</content>
                              </paragraph>
                              <paragraph>Levetiracetam is rapidly and almost completely absorbed after oral administration. Levetiracetam injection and tablets are bioequivalent. The pharmacokinetics of levetiracetam are linear and time-invariant, with low intra- and inter-subject variability. Levetiracetam is not significantly protein-bound (&lt;10% bound) and its volume of distribution is close to the volume of intracellular and extracellular water. Sixty-six percent (66%) of the dose is renally excreted unchanged. The major metabolic pathway of levetiracetam (24% of dose) is an enzymatic hydrolysis of the acetamide group. It is not liver cytochrome P450 dependent. The metabolites have no known pharmacological activity and are renally excreted. Plasma half-life of levetiracetam across studies is approximately 6 to 8 hours. It is increased in the elderly (primarily due to impaired renal clearance) and in subjects with renal impairment.</paragraph>
                           </text>
                           <effectiveTime value="20210519"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s62">
                           <id root="34f97a49-2691-18d1-e063-6394a90acaff"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>The equivalence of levetiracetam injection and the oral formulation was demonstrated in a bioavailability study of 17 healthy volunteers. In this study, levetiracetam 1,500 mg was diluted in 100 mL 0.9% sterile saline solution and was infused over 15 minutes. The selected infusion rate provided plasma concentrations of levetiracetam at the end of the infusion period similar to those achieved at T
 
  <sub>max</sub>after an equivalent oral dose. It is demonstrated that levetiracetam 1,500 mg intravenous infusion is equivalent to levetiracetam 3 x 500 mg oral tablets. The time independent pharmacokinetic profile of levetiracetam was demonstrated following 1,500 mg intravenous infusion for 4 days with BID dosing. The AUC
 
  <sub>(0-12)</sub>at steady-state was equivalent to AUC
 
  <sub>inf</sub>following an equivalent single dose.

 </paragraph>
                              <paragraph>Levetiracetam and its major metabolite are less than 10% bound to plasma proteins; clinically significant interactions with other drugs through competition for protein binding sites are therefore unlikely.</paragraph>
                           </text>
                           <effectiveTime value="20210519"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s63">
                           <id root="34f97a49-2692-18d1-e063-6394a90acaff"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Metabolism</content>
                              </paragraph>
                              <paragraph>Levetiracetam is not extensively metabolized in humans. The major metabolic pathway is the enzymatic hydrolysis of the acetamide group, which produces the carboxylic acid metabolite, ucb L057 (24% of dose) and is not dependent on any liver cytochrome P450 isoenzymes. The major metabolite is inactive in animal seizure models. Two minor metabolites were identified as the product of hydroxylation of the 2-oxo-pyrrolidine ring (2% of dose) and opening of the 2-oxo-pyrrolidine ring in position 5 (1% of dose). There is no enantiomeric interconversion of levetiracetam or its major metabolite.</paragraph>
                           </text>
                           <effectiveTime value="20210519"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s64">
                           <id root="34f97a49-2693-18d1-e063-6394a90acaff"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                              <paragraph>Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose, route of administration or repeated administration. Levetiracetam is eliminated from the systemic circulation by renal excretion as unchanged drug which represents 66% of administered dose. The total body clearance is 0.96 mL/min/kg and the renal clearance is 0.6 mL/min/kg. The mechanism of excretion is glomerular filtration with subsequent partial tubular reabsorption. The metabolite ucb L057 is excreted by glomerular filtration and active tubular secretion with a renal clearance of 4 mL/min/kg. Levetiracetam elimination is correlated to creatinine clearance. Levetiracetam clearance is reduced in patients with renal impairment
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#s16">2.5</linkHtml>) and Use in Specific Populations (
  
   <linkHtml href="#s50">8.6</linkHtml>)].
 
  </content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20210519"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s65">
                           <id root="34f97a49-2694-18d1-e063-6394a90acaff"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20210519"/>
                           <component>
                              <section ID="s66">
                                 <id root="34f97a49-2695-18d1-e063-6394a90acaff"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Elderly</content>
                                    </paragraph>
                                    <paragraph>Pharmacokinetics of levetiracetam were evaluated in 16 elderly subjects (age 61 to 88 years) with creatinine clearance ranging from 30 to 74 mL/min. Following oral administration of twice-daily dosing for 10 days, total body clearance decreased by 38% and the half-life was 2.5 hours longer in the elderly compared to healthy adults. This is most likely due to the decrease in renal function in these subjects.</paragraph>
                                 </text>
                                 <effectiveTime value="20210519"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s67">
                                 <id root="34f97a49-2696-18d1-e063-6394a90acaff"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Pregnancy</content>
                                    </paragraph>
                                    <paragraph>Levetiracetam levels may decrease during pregnancy
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#s31">5.8</linkHtml>) and Use in Specific Populations (
  
   <linkHtml href="#s39">8.1</linkHtml>)].
 
  </content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20210519"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s68">
                                 <id root="34f97a49-2697-18d1-e063-6394a90acaff"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Gender</content>
                                    </paragraph>
                                    <paragraph>Levetiracetam C
 
  <sub>max</sub>and AUC were 20% higher in women (N=11) compared to men (N=12). However, clearances adjusted for body weight were comparable.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20210519"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s69">
                                 <id root="34f97a49-2698-18d1-e063-6394a90acaff"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Race</content>
                                    </paragraph>
                                    <paragraph>Formal pharmacokinetic studies of the effects of race have not been conducted. Cross study comparisons involving Caucasians (N=12) and Asians (N=12), however, show that pharmacokinetics of levetiracetam were comparable between the two races. Because levetiracetam is primarily renally excreted and there are no important racial differences in creatinine clearance, pharmacokinetic differences due to race are not expected.</paragraph>
                                 </text>
                                 <effectiveTime value="20210519"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s70">
                                 <id root="34f97a49-2699-18d1-e063-6394a90acaff"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Renal Impairment</content>
                                    </paragraph>
                                    <paragraph>The disposition of levetiracetam was studied in adult subjects with varying degrees of renal function. Total body clearance of levetiracetam is reduced in patients with impaired renal function by 40% in the mild group (CLcr = 50 to 80 mL/min), 50% in the moderate group (CLcr = 30 to 50 mL/min) and 60% in the severe renal impairment group (CLcr &lt;30 mL/min). Clearance of levetiracetam is correlated with creatinine clearance.</paragraph>
                                    <paragraph>In anuric (end stage renal disease) patients, the total body clearance decreased 70% compared to normal subjects (CLcr &gt;80 mL/min). Approximately 50% of the pool of levetiracetam in the body is removed during a standard 4 hour hemodialysis procedure
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#s16">2.5</linkHtml>)]
 
  </content>.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20210519"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s71">
                                 <id root="34f97a49-269a-18d1-e063-6394a90acaff"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Hepatic Impairment</content>
                                    </paragraph>
                                    <paragraph>In subjects with mild (Child-Pugh A) to moderate (Child-Pugh B) hepatic impairment, the pharmacokinetics of levetiracetam were unchanged. In patients with severe hepatic impairment (Child-Pugh C), total body clearance was 50% that of normal subjects, but decreased renal clearance accounted for most of the decrease. No dose adjustment is needed for patients with hepatic impairment.</paragraph>
                                 </text>
                                 <effectiveTime value="20210519"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s72">
                           <id root="34f97a49-269b-18d1-e063-6394a90acaff"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interactions</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">In vitro</content>data on metabolic interactions indicate that levetiracetam is unlikely to produce, or be subject to, pharmacokinetic interactions. Levetiracetam and its major metabolite, at concentrations well above C
 
  <sub>max</sub>levels achieved within the therapeutic dose range, are neither inhibitors of nor high affinity substrates for human liver cytochrome P450 isoforms, epoxide hydrolase or UDP-glucuronidation enzymes. In addition, levetiracetam does not affect the
 
  <content styleCode="italics">in vitro</content>glucuronidation of valproic acid.

 </paragraph>
                              <paragraph>Potential pharmacokinetic interactions of or with levetiracetam were assessed in clinical pharmacokinetic studies (phenytoin, valproate, warfarin, digoxin, oral contraceptive, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.</paragraph>
                           </text>
                           <effectiveTime value="20210519"/>
                           <component>
                              <section ID="s73">
                                 <id root="34f97a49-269c-18d1-e063-6394a90acaff"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Phenytoin</content>
                                    </paragraph>
                                    <paragraph>Levetiracetam (3,000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy. Pharmacokinetics of levetiracetam were also not affected by phenytoin.</paragraph>
                                 </text>
                                 <effectiveTime value="20210519"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s74">
                                 <id root="34f97a49-269d-18d1-e063-6394a90acaff"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Valproate</content>
                                    </paragraph>
                                    <paragraph>Levetiracetam (1,500 mg twice daily) did not alter the pharmacokinetics of valproate in healthy volunteers. Valproate 500 mg twice daily did not modify the rate or extent of levetiracetam absorption or its plasma clearance or urinary excretion. There also was no effect on exposure to and the excretion of the primary metabolite, ucb L057.</paragraph>
                                 </text>
                                 <effectiveTime value="20210519"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s75">
                                 <id root="34f97a49-269e-18d1-e063-6394a90acaff"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Other Antiepileptic Drugs</content>
                                    </paragraph>
                                    <paragraph>Potential drug interactions between levetiracetam and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies. These data indicate that levetiracetam does not influence the plasma concentration of other AEDs and that these AEDs do not influence the pharmacokinetics of levetiracetam.</paragraph>
                                 </text>
                                 <effectiveTime value="20210519"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s76">
                                 <id root="34f97a49-269f-18d1-e063-6394a90acaff"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Oral Contraceptives</content>
                                    </paragraph>
                                    <paragraph>Levetiracetam (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely. Coadministration of this oral contraceptive did not influence the pharmacokinetics of levetiracetam.</paragraph>
                                 </text>
                                 <effectiveTime value="20210519"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s77">
                                 <id root="34f97a49-26a0-18d1-e063-6394a90acaff"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Digoxin</content>
                                    </paragraph>
                                    <paragraph>Levetiracetam (1,000 mg twice daily) did not influence the pharmacokinetics and pharmacodynamics (ECG) of digoxin given as a 0.25 mg dose every day. Coadministration of digoxin did not influence the pharmacokinetics of levetiracetam.</paragraph>
                                 </text>
                                 <effectiveTime value="20210519"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s78">
                                 <id root="34f97a49-26a1-18d1-e063-6394a90acaff"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Warfarin</content>
                                    </paragraph>
                                    <paragraph>Levetiracetam (1,000 mg twice daily) did not influence the pharmacokinetics of R and S warfarin. Prothrombin time was not affected by levetiracetam. Coadministration of warfarin did not affect the pharmacokinetics of levetiracetam.</paragraph>
                                 </text>
                                 <effectiveTime value="20210519"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s79">
                                 <id root="34f97a49-26a2-18d1-e063-6394a90acaff"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Probenecid</content>
                                    </paragraph>
                                    <paragraph>Probenecid, a renal tubular secretion blocking agent, administered at a dose of 500 mg four times a day, did not change the pharmacokinetics of levetiracetam 1,000 mg twice daily. C
 
  <sup>ss</sup>
                                       <sub>max</sub>of the metabolite, ucb L057, was approximately doubled in the presence of probenecid while the fraction of drug excreted unchanged in the urine remained the same. Renal clearance of ucb L057 in the presence of probenecid decreased 60%, probably related to competitive inhibition of tubular secretion of ucb L057. The effect of levetiracetam on probenecid was not studied.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20210519"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s80">
               <id root="34f97a49-26a3-18d1-e063-6394a90acaff"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20210519"/>
               <component>
                  <section ID="s81">
                     <id root="34f97a49-26a4-18d1-e063-6394a90acaff"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <effectiveTime value="20210519"/>
                     <component>
                        <section ID="s82">
                           <id root="34f97a49-26a5-18d1-e063-6394a90acaff"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Carcinogenesis</content>
                              </paragraph>
                              <paragraph>Rats were dosed with levetiracetam in the diet for 104 weeks at doses of 50, 300 and 1,800 mg/kg/day. Plasma exposure (AUC) at the highest dose was approximately 6 times that in humans at the maximum recommended human dose (MRHD) of 3,000 mg. There was no evidence of carcinogenicity. In mice, oral administration of levetiracetam for 80 weeks (doses up to 960 mg/kg/day) or 2 years (doses up to 4,000 mg/kg/day, lowered to 3,000 mg/kg/day after 45 weeks due to intolerability) was not associated with an increase in tumors. The highest dose tested in mice for 2 years (3,000 mg/kg/day) is approximately 5 times the MRHD on a body surface area (mg/m
 
  <sup>2</sup>) basis.

 </paragraph>
                           </text>
                           <effectiveTime value="20210519"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s83">
                           <id root="34f97a49-26a6-18d1-e063-6394a90acaff"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mutagenesis</content>
                              </paragraph>
                              <paragraph>Levetiracetam was negative in
 
  <content styleCode="italics">in vitro</content>(Ames, chromosomal aberration in mammalian cells) and
 
  <content styleCode="italics">in vivo</content>(mouse micronucleus) assays. The major human metabolite of levetiracetam (ucb L057) was negative in
 
  <content styleCode="italics">in vitro</content>(Ames, mouse lymphoma) assays.

 </paragraph>
                           </text>
                           <effectiveTime value="20210519"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s84">
                           <id root="34f97a49-26a7-18d1-e063-6394a90acaff"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Impairment of Fertility</content>
                              </paragraph>
                              <paragraph>No adverse effects on male or female fertility or reproductive performance were observed in rats at oral doses up to 1,800 mg/kg/day, which were associated with plasma exposures (AUC) up to approximately 6 times that in humans at the MRHD.</paragraph>
                           </text>
                           <effectiveTime value="20210519"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s85">
               <id root="34f97a49-26a8-18d1-e063-6394a90acaff"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>All clinical studies supporting the efficacy of levetiracetam utilized oral formulations. The finding of efficacy of levetiracetam injection is based on the results of studies using an oral formulation of levetiracetam, and on the demonstration of comparable bioavailability of the oral and parenteral formulations
 
  <content styleCode="italics">[see Pharmacokinetics (
  
   <linkHtml href="#s60">12.3</linkHtml>)]
 
  </content>.

 </paragraph>
               </text>
               <effectiveTime value="20210519"/>
               <component>
                  <section ID="s86">
                     <id root="34f97a49-26a9-18d1-e063-6394a90acaff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Partial-Onset Seizures</title>
                     <text>
                        <paragraph>The effectiveness of levetiracetam as adjunctive therapy (added to other antiepileptic drugs) in adults was established in three multicenter, randomized, double-blind, placebo-controlled clinical studies in patients who had refractory partial-onset seizures with or without secondary generalization. The tablet formulation was used in all these studies. In these studies, 904 patients were randomized to placebo, 1,000 mg, 2,000 mg, or 3,000 mg/day. Patients enrolled in Study 1 or Study 2 had refractory partial-onset seizures for at least two years and had taken two or more classical AEDs. Patients enrolled in Study 3 had refractory partial-onset seizures for at least 1 year and had taken one classical AED. At the time of the study, patients were taking a stable dose regimen of at least one and could take a maximum of two AEDs. During the baseline period, patients had to have experienced at least two partial-onset seizures during each 4-week period.</paragraph>
                     </text>
                     <effectiveTime value="20210519"/>
                     <component>
                        <section ID="s87">
                           <id root="34f97a49-26aa-18d1-e063-6394a90acaff"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Study 1</content>
                              </paragraph>
                              <paragraph>Study 1 was a double-blind, placebo-controlled, parallel-group study conducted at 41 sites in the United States comparing levetiracetam 1,000 mg/day (N=97), levetiracetam 3,000 mg/day (N=101), and placebo (N=95) given in equally divided doses twice daily. After a prospective baseline period of 12 weeks, patients were randomized to one of the three treatment groups described above. The 18-week treatment period consisted of a 6-week titration period, followed by a 12-week fixed dose evaluation period, during which concomitant AED regimens were held constant. The primary measure of effectiveness was a between group comparison of the percent reduction in weekly partial seizure frequency relative to placebo over the entire randomized treatment period (titration + evaluation period). Secondary outcome variables included the responder rate (incidence of patients with ≥50% reduction from baseline in partial-onset seizure frequency). The results of the analysis of Study 1 are displayed in
 
  <linkHtml href="#t7">Table 7</linkHtml>.

 </paragraph>
                              <table ID="t7" width="100%">
                                 <caption>Table 7: Reduction in Mean Over Placebo in Weekly Frequency of Partial-Onset Seizures in Study 1</caption>
                                 <col width="41.685%" align="left"/>
                                 <col width="13.778%" align="left"/>
                                 <col width="22.281%" align="left"/>
                                 <col width="22.256%" align="left"/>
                                 <tfoot>
                                    <tr>
                                       <td colspan="4" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>*</sup>
                                             <content styleCode="italics">Statistically significant versus placebo</content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td align="left" styleCode="Toprule Botrule Lrule Rrule" valign="top"/>
                                       <td align="center" styleCode="Toprule Botrule Rrule" valign="top">
                                          <content styleCode="bold">Placebo 
      <br/>  (N=95)
     </content>
                                       </td>
                                       <td align="center" styleCode="Toprule Botrule Rrule" valign="top">
                                          <content styleCode="bold">Levetiracetam 1,000 mg/day 
      <br/>  (N=97)
     </content>
                                       </td>
                                       <td align="center" styleCode="Toprule Botrule Rrule" valign="top">
                                          <content styleCode="bold">Levetiracetam 3,000 mg/day 
      <br/>  (N=101)
     </content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" styleCode="Botrule Lrule Rrule" valign="middle">Percent reduction in partial seizure frequency over placebo</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="middle">–</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="middle">26.1%
    
     <sup>*</sup>
                                       </td>
                                       <td align="center" styleCode="Botrule Rrule" valign="middle">30.1%
    
     <sup>*</sup>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>The percentage of patients (y-axis) who achieved ≥50% reduction in weekly seizure rates from baseline in partial-onset seizure frequency over the entire randomized treatment period (titration + evaluation period) within the three treatment groups (x-axis) is presented in
 
  <linkHtml href="#fig1">Figure 1</linkHtml>. 
  <br/>
                                 <br/>
                              </paragraph>
                              <paragraph ID="fig1" styleCode="MultiMediaCaption">
                                 <content styleCode="bold">Figure 1: Responder Rate (≥50% Reduction from Baseline) in Study 1</content>
                              </paragraph>
                              <renderMultiMedia ID="f02" referencedObject="mm02"/>
                           </text>
                           <effectiveTime value="20210519"/>
                           <component>
                              <observationMedia ID="mm02">
                                 <text>Figure 1
</text>
                                 <value mediaType="image/jpeg" xsi:type="ED">
                                    <reference value="lev18-0003-02.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s88">
                           <id root="34f97a49-26ab-18d1-e063-6394a90acaff"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Study 2</content>
                              </paragraph>
                              <paragraph>Study 2 was a double-blind, placebo-controlled, crossover study conducted at 62 centers in Europe comparing levetiracetam 1,000 mg/day (N=106), levetiracetam 2,000 mg/day (N=105), and placebo (N=111) given in equally divided doses twice daily.</paragraph>
                              <paragraph>The first period of the study (Period A) was designed to be analyzed as a parallel-group study. After a prospective baseline period of up to 12 weeks, patients were randomized to one of the three treatment groups described above. The 16-week treatment period consisted of the 4-week titration period followed by a 12-week fixed dose evaluation period, during which concomitant AED regimens were held constant. The primary measure of effectiveness was a between group comparison of the percent reduction in weekly partial seizure frequency relative to placebo over the entire randomized treatment period (titration + evaluation period). Secondary outcome variables included the responder rate (incidence of patients with ≥50% reduction from baseline in partial-onset seizure frequency). The results of the analysis of Period A are displayed in
 
  <linkHtml href="#t8">Table 8</linkHtml>.

 </paragraph>
                              <table ID="t8" width="100%">
                                 <caption>Table 8: Reduction in Mean Over Placebo in Weekly Frequency of Partial-Onset Seizures in Study 2: Period A</caption>
                                 <col width="36.450%" align="left"/>
                                 <col width="14.600%" align="left"/>
                                 <col width="22.925%" align="left"/>
                                 <col width="26.025%" align="left"/>
                                 <tfoot>
                                    <tr>
                                       <td colspan="4" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>*</sup>
                                             <content styleCode="italics">Statistically significant versus placebo</content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td align="left" styleCode="Toprule Botrule Lrule Rrule" valign="top"/>
                                       <td align="center" styleCode="Toprule Botrule Rrule" valign="top">
                                          <content styleCode="bold">Placebo 
      <br/>  (N=111)
     </content>
                                       </td>
                                       <td align="center" styleCode="Toprule Botrule Rrule" valign="top">
                                          <content styleCode="bold">Levetiracetam 1,000 mg/day 
      <br/>  (N=106)
     </content>
                                       </td>
                                       <td align="center" styleCode="Toprule Botrule Rrule" valign="top">
                                          <content styleCode="bold">Levetiracetam 2,000 mg/day 
      <br/>  (N=105)
     </content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" styleCode="Botrule Lrule Rrule" valign="middle">Percent reduction in partial seizure frequency over placebo</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="middle">–</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="middle">17.1%
    
     <sup>*</sup>
                                       </td>
                                       <td align="center" styleCode="Botrule Rrule" valign="middle">21.4%
    
     <sup>*</sup>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>The percentage of patients (y-axis) who achieved ≥50% reduction in weekly seizure rates from baseline in partial-onset seizure frequency over the entire randomized treatment period (titration + evaluation period) within the three treatment groups (x-axis) is presented in
 
  <linkHtml href="#fig2">Figure 2</linkHtml>. 
  <br/>
                                 <br/>
                              </paragraph>
                              <paragraph ID="fig2" styleCode="MultiMeidaCaption">
                                 <content styleCode="bold">Figure 2: Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A</content>
                              </paragraph>
                              <renderMultiMedia ID="f03" referencedObject="mm03"/>
                              <paragraph>The comparison of levetiracetam 2,000 mg/day to levetiracetam 1,000 mg/day for responder rate was statistically significant (
 
  <content styleCode="italics">P</content>=0.02). Analysis of the trial as a cross-over yielded similar results.

 </paragraph>
                           </text>
                           <effectiveTime value="20210519"/>
                           <component>
                              <observationMedia ID="mm03">
                                 <text>Figure 2
</text>
                                 <value mediaType="image/jpeg" xsi:type="ED">
                                    <reference value="lev18-0003-03.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s89">
                           <id root="34f97a49-26ac-18d1-e063-6394a90acaff"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Study 3</content>
                              </paragraph>
                              <paragraph>Study 3 was a double-blind, placebo-controlled, parallel-group study conducted at 47 centers in Europe comparing levetiracetam 3,000 mg/day (N=180) and placebo (N=104) in patients with refractory partial-onset seizures, with or without secondary generalization, receiving only one concomitant AED. Study drug was given in two divided doses. After a prospective baseline period of 12 weeks, patients were randomized to one of two treatment groups described above. The 16-week treatment period consisted of a 4-week titration period, followed by a 12-week fixed dose evaluation period, during which concomitant AED doses were held constant. The primary measure of effectiveness was a between group comparison of the percent reduction in weekly seizure frequency relative to placebo over the entire randomized treatment period (titration + evaluation period). Secondary outcome variables included the responder rate (incidence of patients with ≥50% reduction from baseline in partial-onset seizure frequency).
 
  <linkHtml href="#t9">Table 9</linkHtml>displays the results of the analysis of Study 3.

 </paragraph>
                              <table ID="t9" width="100%">
                                 <caption>Table 9: Reduction in Mean Over Placebo in Weekly Frequency of Partial-Onset Seizures in Study 3</caption>
                                 <col width="53.718%" align="left"/>
                                 <col width="19.140%" align="left"/>
                                 <col width="27.142%" align="left"/>
                                 <tfoot>
                                    <tr>
                                       <td colspan="3" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>*</sup>
                                             <content styleCode="italics">Statistically significant versus placebo</content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td align="left" styleCode="Toprule Botrule Lrule Rrule" valign="middle"/>
                                       <td align="center" styleCode="Toprule Botrule Rrule" valign="middle">
                                          <content styleCode="bold">Placebo 
      <br/>  (N=104)
     </content>
                                       </td>
                                       <td align="center" styleCode="Toprule Botrule Rrule" valign="middle">
                                          <content styleCode="bold">Levetiracetam 3,000 mg/day 
      <br/>  (N=180)
     </content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" styleCode="Botrule Lrule Rrule" valign="middle">Percent reduction in partial seizure frequency over placebo</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="middle">–</td>
                                       <td align="center" styleCode="Botrule Rrule" valign="middle">23.0%
    
     <sup>*</sup>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>The percentage of patients (y-axis) who achieved ≥50% reduction in weekly seizure rates from baseline in partial-onset seizure frequency over the entire randomized treatment period (titration + evaluation period) within the two treatment groups (x-axis) is presented in
 
  <linkHtml href="#fig3">Figure 3</linkHtml>. 
  <br/>
                                 <br/>
                              </paragraph>
                              <paragraph ID="fig3" styleCode="MultiMeidaCaption">
                                 <content styleCode="bold">Figure 3: Responder Rate (≥50% Reduction from Baseline) in Study 3</content>
                              </paragraph>
                              <renderMultiMedia ID="f04" referencedObject="mm04"/>
                           </text>
                           <effectiveTime value="20210519"/>
                           <component>
                              <observationMedia ID="mm04">
                                 <text>Figure 3
</text>
                                 <value mediaType="image/jpeg" xsi:type="ED">
                                    <reference value="lev18-0003-04.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s90">
                     <id root="34f97a49-26ad-18d1-e063-6394a90acaff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2 Myoclonic Seizures in Patients with Juvenile Myoclonic Epilepsy</title>
                     <text>
                        <paragraph>The effectiveness of levetiracetam as adjunctive therapy in patients with juvenile myoclonic epilepsy (JME) experiencing myoclonic seizures was established in one multicenter, randomized, double-blind, placebo-controlled study, conducted at 37 sites in 14 countries. Of the 120 patients enrolled, 113 had a diagnosis of confirmed or suspected JME. Eligible patients on a stable dose of 1 antiepileptic drug (AED) experiencing one or more myoclonic seizures per day for at least 8 days during the prospective 8-week baseline period were randomized to either levetiracetam or placebo (levetiracetam N=60, placebo N=60). Patients were titrated over 4 weeks to a target dose of 3,000 mg/day and treated at a stable dose of 3,000 mg/day over 12 weeks (evaluation period). Study drug was given in 2 divided doses. The primary measure of effectiveness was the proportion of patients with at least 50% reduction in the number of days per week with one or more myoclonic seizures during the treatment period (titration + evaluation periods) as compared to baseline.
 
  <linkHtml href="#t10">Table 10</linkHtml>displays the results for the 113 patients with JME in this study. Of 120 patients enrolled, 113 had a diagnosis of confirmed or suspected JME. The results are displayed in
 
  <linkHtml href="#t10">Table 10</linkHtml>.

 </paragraph>
                        <table ID="t10" width="100%">
                           <caption>Table 10: Responder Rate (≥50% Reduction from Baseline) in Myoclonic Seizure Days per Week for Patients with JME</caption>
                           <col width="48.117%" align="left"/>
                           <col width="20.493%" align="left"/>
                           <col width="31.390%" align="left"/>
                           <tfoot>
                              <tr>
                                 <td colspan="3" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>*</sup>
                                       <content styleCode="italics">Statistically significant versus placebo</content>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="left" styleCode="Toprule Botrule Lrule Rrule" valign="middle"/>
                                 <td align="center" styleCode="Toprule Botrule Rrule" valign="middle">
                                    <content styleCode="bold">Placebo 
      <br/>  (N=59)
     </content>
                                 </td>
                                 <td align="center" styleCode="Toprule Botrule Rrule" valign="middle">
                                    <content styleCode="bold">Levetiracetam 
      <br/>  (N=54)
     </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="middle">Percentage of responders</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="middle">23.7%</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="middle">60.4%
    
     <sup>*</sup>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20210519"/>
                  </section>
               </component>
               <component>
                  <section ID="s91">
                     <id root="34f97a49-26ae-18d1-e063-6394a90acaff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.3 Primary Generalized Tonic-Clonic Seizures</title>
                     <text>
                        <paragraph>The effectiveness of levetiracetam as adjunctive therapy in patients with idiopathic generalized epilepsy experiencing primary generalized tonic-clonic (PGTC) seizures was established in one multicenter, randomized, double-blind, placebo-controlled study, conducted at 50 sites in 8 countries. Eligible patients on a stable dose of 1 or 2 antiepileptic drugs (AEDs) experiencing at least 3 PGTC seizures during the 8-week combined baseline period (at least one PGTC seizure during the 4 weeks prior to the prospective baseline period and at least one PGTC seizure during the 4-week prospective baseline period) were randomized to either levetiracetam or placebo. The 8-week combined baseline period is referred to as “baseline” in the remainder of this section. The population included 164 patients (levetiracetam N=80, placebo N=84) with idiopathic generalized epilepsy (predominately juvenile myoclonic epilepsy, juvenile absence epilepsy, childhood absence epilepsy, or epilepsy with Grand Mal seizures on awakening) experiencing primary generalized tonic-clonic seizures. Each of these syndromes of idiopathic generalized epilepsy was well represented in this patient population. Patients were titrated over 4 weeks to a target dose of 3,000 mg/day for adults or a pediatric target dose of 60 mg/kg/day and treated at a stable dose of 3,000 mg/day (or 60 mg/kg/day for children) over 20 weeks (evaluation period). Study drug was given in 2 equally divided doses per day.</paragraph>
                        <paragraph>The primary measure of effectiveness was the percent reduction from baseline in weekly PGTC seizure frequency for levetiracetam and placebo treatment groups over the treatment period (titration + evaluation periods). There was a statistically significant decrease from baseline in PGTC frequency in the levetiracetam-treated patients compared to the placebo-treated patients.</paragraph>
                        <table ID="t11" width="100%">
                           <caption>Table 11: Median Percent Reduction from Baseline in PGTC Seizure Frequency per Week</caption>
                           <col width="51.000%" align="left"/>
                           <col width="21.867%" align="left"/>
                           <col width="27.133%" align="left"/>
                           <tfoot>
                              <tr>
                                 <td colspan="3" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>*</sup>
                                       <content styleCode="italics">Statistically significant versus placebo</content>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="left" styleCode="Toprule Botrule Lrule Rrule" valign="middle"/>
                                 <td align="center" styleCode="Toprule Botrule Rrule" valign="middle">
                                    <content styleCode="bold">Placebo</content>
                                    <br/>
                                    <content styleCode="bold">(N=84)</content>
                                 </td>
                                 <td align="center" styleCode="Toprule Botrule Rrule" valign="middle">
                                    <content styleCode="bold">Levetiracetam 
      <br/>  (N=78)
     </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="middle">Percentage reduction in PGTC seizure frequency</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="middle">44.6%</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="middle">77.6%
    
     <sup>*</sup>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The percentage of patients (y-axis) who achieved ≥50% reduction in weekly seizure rates from baseline in PGTC seizure frequency over the entire randomized treatment period (titration + evaluation period) within the two treatment groups (x-axis) is presented in
 
  <linkHtml href="#fig4">Figure 4</linkHtml>. 
  <br/>
                           <br/>
                        </paragraph>
                        <paragraph ID="fig4" styleCode="MultiMeidaCaption">
                           <content styleCode="bold">Figure 4: Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week</content>
                        </paragraph>
                        <renderMultiMedia ID="f05" referencedObject="mm05"/>
                     </text>
                     <effectiveTime value="20210519"/>
                     <component>
                        <observationMedia ID="mm05">
                           <text>Figure 4
</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="lev18-0003-05.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s92">
               <id root="34f97a49-26af-18d1-e063-6394a90acaff"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20210519"/>
               <component>
                  <section ID="s93">
                     <id root="34f97a49-26b0-18d1-e063-6394a90acaff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>16.1 How Supplied</title>
                     <text>
                        <paragraph>Levetiracetam in Sodium Chloride Injection is supplied as follows:</paragraph>
                        <table width="100%" styleCode="Noautorules">
                           <col width="17.233%" align="left"/>
                           <col width="59.633%" align="left"/>
                           <col width="23.133%" align="left"/>
                           <tbody>
                              <tr>
                                 <td align="left" valign="bottom">
                                    <content styleCode="bold">NDC</content>
                                 </td>
                                 <td align="left" valign="bottom">
                                    <content styleCode="bold">Levetiracetam in 0.82% Sodium Chloride Injection 
      <br/>  (5 mg per mL)
     </content>
                                 </td>
                                 <td align="left" valign="bottom">
                                    <content styleCode="bold">Package Factor</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top">70860-602-82</td>
                                 <td align="left" valign="bottom">500 mg per 100 mL ready-to-infuse solution in a single-dose bag</td>
                                 <td align="left" valign="bottom">10 bags per carton</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="bottom">
                                    <content styleCode="bold"> </content>
                                 </td>
                                 <td align="left" valign="bottom"/>
                                 <td align="left" valign="bottom"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="bottom">
                                    <content styleCode="bold">NDC</content>
                                 </td>
                                 <td align="left" valign="bottom">
                                    <content styleCode="bold">Levetiracetam in 0.75% Sodium Chloride Injection 
      <br/>  (10 mg per mL)
     </content>
                                 </td>
                                 <td align="left" valign="bottom">
                                    <content styleCode="bold">Package Factor</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top">70860-603-82</td>
                                 <td align="left" valign="bottom">1,000 mg per 100 mL ready-to-infuse solution in a single-dose bag</td>
                                 <td align="left" valign="bottom">10 bags per carton</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="bottom">
                                    <content styleCode="bold"> </content>
                                 </td>
                                 <td align="left" valign="bottom"/>
                                 <td align="left" valign="bottom"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="bottom">
                                    <content styleCode="bold">NDC</content>
                                 </td>
                                 <td align="left" valign="bottom">
                                    <content styleCode="bold">Levetiracetam in 0.54% Sodium Chloride Injection 
      <br/>  (15 mg per mL)
     </content>
                                 </td>
                                 <td align="left" valign="bottom">
                                    <content styleCode="bold">Package Factor</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top">70860-604-82</td>
                                 <td align="left" valign="bottom">1,500 mg per 100 mL ready-to-infuse solution in a single-dose bag</td>
                                 <td align="left" valign="bottom">10 bags per carton</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Levetiracetam in Sodium Chloride Injection is a clear, colorless, sterile solution that is available in a single-dose 100 mL dual port bag with an aluminum overwrap.</paragraph>
                     </text>
                     <effectiveTime value="20210519"/>
                  </section>
               </component>
               <component>
                  <section ID="s94">
                     <id root="34f97a49-26b1-18d1-e063-6394a90acaff"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <title>16.2 Storage</title>
                     <text>
                        <paragraph>Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]</paragraph>
                        <paragraph>
                           <content styleCode="bold">Sterile, Nonpyrogenic, Preservative-free, PVC-free. 
   <br/>  The container closure is not made with natural rubber latex.
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20210519"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s95">
               <id root="34f97a49-26b2-18d1-e063-6394a90acaff"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <effectiveTime value="20210519"/>
               <component>
                  <section ID="s96">
                     <id root="34f97a49-26b3-18d1-e063-6394a90acaff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Psychiatric Reactions and Changes in Behavior</content>
                        </paragraph>
                        <paragraph>Advise patients and their caregivers that levetiracetam may cause changes in behavior (e.g., aggression, agitation, anger, anxiety, apathy, depression, hostility, and irritability) and psychotic symptoms
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#s22">5.1</linkHtml>)].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20210519"/>
                  </section>
               </component>
               <component>
                  <section ID="s97">
                     <id root="34f97a49-26b4-18d1-e063-6394a90acaff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Effects on Driving or Operating Machinery</content>
                        </paragraph>
                        <paragraph>Inform patients that levetiracetam may cause dizziness and somnolence. Inform patients not to drive or operate machinery until they have gained sufficient experience on levetiracetam to gauge whether it adversely affects their ability to drive or operate machinery
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#s23">5.2</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20210519"/>
                  </section>
               </component>
               <component>
                  <section ID="s98">
                     <id root="34f97a49-26b5-18d1-e063-6394a90acaff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Anaphylaxis and Angioedema</content>
                        </paragraph>
                        <paragraph>Advise patients to discontinue levetiracetam and seek medical care if they develop signs and symptoms of anaphylaxis or angioedema
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#s24">5.3</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20210519"/>
                  </section>
               </component>
               <component>
                  <section ID="s99">
                     <id root="34f97a49-26b6-18d1-e063-6394a90acaff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Dermatological Adverse Reactions</content>
                        </paragraph>
                        <paragraph>Advise patients that serious dermatological adverse reactions have occurred in patients treated with levetiracetam and instruct them to call their physician immediately if a rash develops
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#s25">5.4</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20210519"/>
                  </section>
               </component>
               <component>
                  <section ID="s100">
                     <id root="34f97a49-26b7-18d1-e063-6394a90acaff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy</content>
                        </paragraph>
                        <paragraph>Advise patients to notify their healthcare provider if they become pregnant or intend to become pregnant during levetiracetam therapy. Encourage patients to enroll in the North American Antiepileptic Drug (NAAED) pregnancy registry if they become pregnant
 
  <content styleCode="italics">[see Use in Specific Populations (
  
   <linkHtml href="#s39">8.1</linkHtml>)]
 
  </content>.

 </paragraph>
                        <paragraph>
                           <content styleCode="bold">Athenex</content>
                           <br/>  Mfd. for Athenex 
  <br/>  Schaumburg, IL 60173 (USA) 
  <br/>  Made in India 
  <br/>  ©2021 Athenex.

 </paragraph>
                        <paragraph>Revised: May 2021</paragraph>
                     </text>
                     <effectiveTime value="20210519"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s101">
               <id root="34f97a49-26b8-18d1-e063-6394a90acaff"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>PACKAGE LABEL – PRINCIPAL DISPLAY PANEL - BAG</paragraph>
                  <paragraph>NDC 70860-602-41</paragraph>
                  <paragraph>Levetiracetam in 0.82% Sodium Chloride Injection</paragraph>
                  <paragraph>500 mg per 100 mL (5 mg per mL)</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>For Intravenous Infusion Only</paragraph>
                  <paragraph>INFUSE OVER A PERIOD OF 15 MINUTES</paragraph>
                  <renderMultiMedia ID="f06" referencedObject="mm06"/>
               </text>
               <effectiveTime value="20180731"/>
               <component>
                  <observationMedia ID="mm06">
                     <text>PACKAGE LABEL – PRINCIPAL DISPLAY PANEL - BAG
</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="lev18-0003-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s102">
               <id root="34f97a49-26b9-18d1-e063-6394a90acaff"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>PACKAGE LABEL – PRINCIPAL DISPLAY PANEL - BAG</paragraph>
                  <paragraph>NDC 70860-603-41</paragraph>
                  <paragraph>Levetiracetam in 0.75% Sodium Chloride Injection</paragraph>
                  <paragraph>1,000 mg per 100 mL (10 mg per mL)</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>For Intravenous Infusion Only</paragraph>
                  <paragraph>INFUSE OVER A PERIOD OF 15 MINUTES</paragraph>
                  <renderMultiMedia ID="f07" referencedObject="mm07"/>
               </text>
               <effectiveTime value="20180731"/>
               <component>
                  <observationMedia ID="mm07">
                     <text>PACKAGE LABEL – PRINCIPAL DISPLAY PANEL - BAG
</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="lev18-0003-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s103">
               <id root="34f97a49-26ba-18d1-e063-6394a90acaff"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>PACKAGE LABEL – PRINCIPAL DISPLAY PANEL - BAG</paragraph>
                  <paragraph>NDC 70860-604-41</paragraph>
                  <paragraph>Levetiracetam in 0.54% Sodium Chloride Injection</paragraph>
                  <paragraph>1,500 mg per 100 mL (15 mg per mL)</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>For Intravenous Infusion Only</paragraph>
                  <paragraph>INFUSE OVER A PERIOD OF 15 MINUTES</paragraph>
                  <renderMultiMedia ID="f08" referencedObject="mm08"/>
               </text>
               <effectiveTime value="20180731"/>
               <component>
                  <observationMedia ID="mm08">
                     <text>PACKAGE LABEL – PRINCIPAL DISPLAY PANEL - BAG
</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="lev18-0003-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>